Verastem Oncology jumps after announcing CEO transition, pricing $250M securities offering
Verastem Oncology (VSTM) shares rose around 20% in premarket trading on Wednesday after the biopharmaceutical company priced an underwritten offering expected to raise approximately $250M in gross proceeds.
The company priced 30,937,500 shares of common stock at $8.00 per share, along with pre-funded
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.